Dr. Nina Rawal is a and strategic leader dedicated to scaling high-impact innovation in the life sciences sector. With a career spanning investment, strategy, and operational leadership, she has built a strong track record in identifying and accelerating breakthrough healthcare solutions. Dr. Nina Rawal previously served as Partner and Co-Head of Ventures at Trill Impact, created, raised and co-headed Trill Impact Ventures, a USD 100m VC fund, focusing on underserved patient groups. She also led the life science investment team at Industrifonden, managing investments across a €500 million portfolio.
Earlier in her career, she held leadership roles including Vice President of Strategy and Ventures at Gambro and worked as a consultant at Boston Consulting Group in both Stockholm and New York. Her academic background includes an MSc in Biomedicine and a PhD in Molecular Neurobiology from Karolinska Institutet, with research conducted at Columbia University and Hôpital de la Salpêtrière.
Dr. Nina Rawal currently serves as a board member of Cinclus Pharma and sits on the investment committee of We Venture Capital. Recognized as a Young Global Leader by the World Economic Forum, she is committed to advancing innovation that improves outcomes for underserved patients.
Dr. Nina Rawal is a and strategic leader dedicated to scaling high-impact innovation in the life sciences sector. With a career spanning investment, strategy, and operational leadership, she has built a strong track record in identifying and accelerating breakthrough healthcare solutions. Dr. Nina Rawal previously served as Partner and Co-Head of Ventures at Trill Impact, created, raised and co-headed Trill Impact Ventures, a USD 100m VC fund, focusing on underserved patient groups. She also led the life science investment team at Industrifonden, managing investments across a €500 million portfolio.
Earlier in her career, she held leadership roles including Vice President of Strategy and Ventures at Gambro and worked as a consultant at Boston Consulting Group in both Stockholm and New York. Her academic background includes an MSc in Biomedicine and a PhD in Molecular Neurobiology from Karolinska Institutet, with research conducted at Columbia University and Hôpital de la Salpêtrière.
Dr. Nina Rawal currently serves as a board member of Cinclus Pharma and sits on the investment committee of We Venture Capital. Recognized as a Young Global Leader by the World Economic Forum, she is committed to advancing innovation that improves outcomes for underserved patients.
